Liver transplantation and hepatocellular carcinoma

Seminars in Surgical Oncology

Volumn 12, Issue 3, 1996, Pages 212-216

  Yokoyama, Itsuo ^a   Takagi, Hiroshi ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

hepatocellar carcinoma; immunosuppression; liver transplantation; metastasis

Indexed keywords

ARTICLE; CANCER STAGING; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SURGICAL RISK; TREATMENT OUTCOME;

CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; HUMANS; IMMUNOSUPPRESSION; LIVER NEOPLASMS; LIVER TRANSPLANTATION; PATIENT SELECTION; PROGNOSIS;

EID: 0030012927     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2388(199605/06)12:3<212::AID-SSU12>3.0.CO;2-Z     Document Type: Article

References (30)

1. Penn I: Hepatic transplantation for primary and metastatic cancers of the liver. Surgery 110:726-735, 1991.
2. Iwatsuki S, Gordon RD, Shaw BW, Starzl TE: Role of liver transplantation in cancer therapy. Ann Surg 202:401-407, 1985.
3. Nonami T, Yokoyama I, Iwatsuki S, Starzl TE: The incidence of portal vein thrombosis at liver transplantation. Hepatology 16:1195-1198, 1992.
4. Iwatsuki S, Starzl TE, Sheahan DG, et al.: Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 214:211-229, 1991.
5. UNOS: "1994 Report of Center Specific Graft and Patient Survival Rates, Liver Volume," 1995.
6. Edmondson HA, Steiner PE: Primary carcinoma of the liver. Cancer 7:462-503, 1953.
7. Klatzkin G, Conn HO: "Neoplasms of the Liver and Intrahepatic Bile Ducts." Oxford: Oxford Univ Press, 1993, 367-396.
8. Starzl TE, Demetris AJ, Van Thiel D: Liver transplantation. N Eng J Med 321:1092-1099, 1989.
9. Davies SE, Portman BC, O'Grady JG, et al.: Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 13:150-157, 1991.
10. Samuel D, Bismuth A, Mathieu D, et al.: Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 337:813-815, 1991.
11. O'Grady JG, Polson RJ, Rolles K, et al.: Liver transplantation for malignant disease. Ann Surg 207:373-379, 1988.
12. Ismail T, Angrisaui L, Gunson K, et al.: Primary hepatic malignancy: the role of liver transplantation. Br J Surg 77:983-987, 1990.
13. Ringe B, Pichlmayi R, Wittekind C, Tusch G: Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 Patients. World J Surg 15:270-285, 1991.
14. Haug CE, Jenkins RL, Rohrer RJ, et al.: Liver transplantation for primary hepatic cancer. Transplantation 53:376-382, 1992.
15. Bismuth H, Chiche L, Adam R, et al.: Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 218:145-151, 1993.
16. Yokoyama I, Sheahan DG, Carr B, et al.: Clinicopathologic factors affecting patient survival and tumor recurrence after orthotopic liver transplantation for hepatocellular carcinoma. Transplant Proc 23:2194-2196, 1991.
17. Carr BI, Selby R, Madariaga J, et al.: Prolonged survival after liver transplantation and cancer chemotherapy for advanced-stage hepatocellular carcinoma. Transplant Proc 25:1128-1129, 1993.
18. Stone MJ, Klintmalm GBG, Polter D, et al.: Neoadjuvant chemotherapy and liver transplantation for hepatocellular carcinoma: a pilot study in 20 patients. Gastroenterology 104:196-202, 1993.
19. Cherquin D, Piedbois P, Pierga JY, et al.: Multimodal adjuvant treatment and liver transplantation for advanced hepatocellular carcinoma. Cancer 73:2721-2726, 1994.
20. Olthoff KM, Rosove MH, Shackleton CR, et al.: Adjuvant chemotherapy improves survival after liver transplantation for hepatocellular carcinoma. Ann Surg 221:734-743, 1995.
21. US Multicenter FK506 Liver Study Group: A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 311:1110-1114, 1994.
22. European FK506 Multicenter Liver Study Group: FK506 (tacrolimus) vs cyclosporine in liver graft rejection prevention. Lancet i:423-426, 1994.
23. Borrel J, Feurer C, Gubler H, Staehelin H: Biological effects of cyclosporine A: a new antilymphocyte agent. Agents Actions 6:468-475, 1976.
24. Starzl TE, Penn I, Putman CW, et al.: Iatrogenic alterations of immunologic surveillance in man and their influence on malignancy. Transplant Rev 4:112, 1971.
25. Yokoyama I, Carr B, Saitsu H, et al.: Accelerated tumor growth after liver transplantation for hepatocellular carcinoma. Cancer 68:2095-2100, 1991.
26. Weiss L: Metastatic insufficiency. Adv Cancer Res 54:159-211, 1990.
27. Yokoyama I, Hayashi S, Sato E, et al.: Enhancement of tumor proliferation by cyclosporine A in early phase of experimental hepatic metastasis. Jpn J Cancer Res 85:704-709, 1994.
28. Yokoyama I, Hayashi S, Kobayashi T, et al.: Immunosuppressive drugs and their effect on experimental tumor growth. Transplant Int 8:251-255, 1995.
29. Francavilla A, Barone M, Todo S, et al.: Augmentation of rat liver regeneration by FK 506 compared with cyclosporine. Lancet ii:1248-1249, 1989.
30. Blanc P, Etienne H, Daujat M, et al.: Antiproliferative effect of FK 506 and cyclosporine on adult human hepatocytes in culture. Transplant Proc. 23:2821-2824, 1991.